Effect of alkylphospholipids on Candida albicans biofilm formation and maturation

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 1, 2013, Pages 113-125

  Vila, Taissa V M ^a   Ishida, Kelly ^a   de Souza, Wanderley ^a,b   Prousis, Kyriakos ^c   Calogeropoulou, Theodora ^c   Rozental, Sonia ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE METROLOGIA   (Brazil)

^c INSTITUTE OF BIOLOGY   (Greece)

Author keywords

Antifungal; Catheter; Miltefosine; Synthetic analogues; Yeast

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; MILTEFOSINE; TC 106; TC 117; TC 19; TCAN 26; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG SCREENING; FUNGAL CELL; FUNGAL VIABILITY; FUNGICIDAL ACTIVITY; IN VITRO STUDY; INHIBITION KINETICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; PHOSPHOLIPIDS; PHOSPHORYLCHOLINE; PLANKTON; TREATMENT OUTCOME;

EID: 84871203634     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks353     Document Type: Article

References (43)

1. Nucci M, Queiroz Telles F, Tobón AM et al. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 2010; 51: 561-70.
2. Chandra J, Kuhn DM, Mukherjee PK et al. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001; 183: 5385-94.
3. Sifuentes-Osornio J, Corzo-León DE, Ponce-de-León LA. Epidemiology of invasive fungal infections in Latin America. Curr Fungal Infect Rep 2012; 6: 23-34.
4. Bassetti M, Taramasso L, Nicco E et al. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. Plos One 2011; 6: e24198.
5. Colombo AL, Guimaraes T. Epidemiologia das infecções hematogênicas por Candida spp. Rev Soc Bras Med Trop 2003; 5: 599-607.
6. Ramage G, VandeWalle K, Wickes BL et al. Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol 2001; 18: 163-70.
7. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-93.
8. Hawser SP, Douglas LJ. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 1995; 39: 2128-31.
9. Mukherjee PK, Chandra J. Candida biofilm resistance. Drug Resist Updat 2004; 7: 301-9.
10. Ramage G, Bachmann S, Patterson TF et al. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 2002; 49: 973-80.
11. Mukherjee PK, Chandra J, Kuhn DM et al. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 2003; 71: 4333-40.
12. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
13. Kuhn DM, George T, Chandra J et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-80.
14. Widmer F, Wright LC, Obando D et al. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother 2006; 50: 414-21.
15. Avlonitis N, Lekka E, Detsi A et al. Antileishmanial ring-substituted ether phospholipids. J Med Chem 2003; 46: 755-67.
16. Urbina JA. Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites. Trans R Soc Trop Med Hyg 2006; 100: 9-16.
17. Kapou A, Benetis NP, Avlonitis N et al. 3D-Quantitative structure- activity relationships of synthetic antileishmanial ring-substituted ether phospholipids. Bioorg Med Chem 2007; 15: 1252-65.
18. Calogeropoulou T, Angelou P, Detsi A et al. Design and synthesis of potent antileishmanial cycloalkylidene-substituted ether phospholipid derivatives. J Med Chem 2008; 51: 897-908.
19. Chan JH, Neal RA, Pendergast W. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987; 36: 2633-6.
20. Unger C, Maniera T, Kaufmann-Kolle P et al. In vivo antileishmanial activity of hexadecylphosphocholine and other alkylphosphocholines. Drugs Today 1998; 34: 133-40.
21. Croft SL, Seifert K, Duchêne M. Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol 2003; 126: 165-72.
22. Croft SL, Barrett MP, Urbina JA. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 2005; 21: 508-12.
23. Braga-Silva LA, Mesquita DG, Ribeiro DM et al. Trailing end-point phenotype antibiotic-sensitive strains of Candida albicans produce different amounts of aspartyl peptidases. Braz J Med Biol Res 2009; 42: 765-70.
24. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Third Edition: Approved Standard M27-A3. CLSI, Wayne, PA, USA, 2008.
25. Pfaller MA, Sheehan DJ, Rex JH. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev 2004; 17: 268-80.
26. Jin Y, Yip HK, Samaranayake YH et al. Biofilm-forming ability of Candida albicans is unlikely to contribute to high levels of oral yeast carriage in cases of human immunodeficiency virus infection. J Clin Microbiol 2003; 41: 2961-7.
27. Ramage G, VandeWalle K, Wickes BL et al. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001; 45: 2475-9.
28. Braga PC, Culici M, Alfieri M et al. Thymol inhibits Candida albicans biofilm formation and mature biofilm. Int J Antimicrob Agents 2008; 31: 472-7.
29. Kumamoto CA. Candida biofilms. Curr Opin Microbiol 2002; 5: 608-11.
30. Ramage G, Saville SP, Thomas DP et al. Candida biofilms: an update. Eukaryot Cell 2005; 4: 633-8.
31. Mermel LA, Farr BM, Sherertz RJ et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32: 1249-72.
32. Walsh TJ, Rex JH. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis 2002; 32: 600-2.
33. Tumbarello M, Posteraro B, Trecarichi EM et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol 2007; 45: 1843-50.
34. Obando D, Widmer F, Wright LC et al. Synthesis, antifungal and antimicrobial activity of alkylphospholipids. Bioorg Med Chem 2007; 15: 5158-65.
35. Lux H, Hart DT, Parker PJ et al. Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkylphospholipid analogues. Adv Exp Med Biol 1996; 416: 201-11.
36. Zufferey R, Mamoun CB. Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs. Mol Biochem Parasitol 2002; 125: 127-34.
37. Jiménez-López JM, Ríos-Marco P, Marco C et al. Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids. Lipids Health Dis 2010; 9: 33.
38. Chandra J, Patel JD, Li J et al. Modification of surface properties of biomaterials influences the ability of Candida albicans to form biofilms. Appl Environ Microbiol 2005; 71: 8795-801.
39. Breiser A, Kim DJ, Fleer E et al. Distribution and metabolism of hexadecylphosphocholine in mice. Lipids 1987; 22: 925-6.
40. MarschnerN, Kötting J, Eibl H et al. Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steadystate treatment. Cancer Chemother Pharmacol 1992; 31: 18-22.
41. Unger C, Fleer E, Damenz E et al. Hexadecylphosphocholine: determination of serum concentrations in rats. J Lipid Mediat 1991; 3: 71-8.
42. Soto J, Soto P. Miltefosine: oral treatment of leishmaniasis. Expert Rev Anti-Infect Ther 2006; 4: 177-85.
43. Papanastasiou I, Prousis KS, Georgikopoulou K et al. Design and synthesis of new adamantyl-substituted antileishmanial ether phospholipids. Bioorg Med Chem Lett 2010; 20: 5484-7.